Clinical Evidence
The research behind monofilament screening.
The 10-gram Semmes-Weinstein monofilament test is endorsed by every major diabetes care guideline and validated across decades of peer-reviewed research. This page compiles the key evidence.
Guideline Endorsements
Recommended by every major clinical authority.
The 10-gram monofilament test is not experimental, it is the accepted standard of care, embedded in the evidence-based clinical guidelines that govern diabetes management worldwide.
Standards of Care in Diabetes, 2025
"The examination should include assessment for loss of protective sensation (LOPS) using the 10-g monofilament along with at least one other neurological assessment tool."
The ADA recommends comprehensive foot exams at least annually for all patients with diabetes, and at every visit for patients with elevated risk. The 10-gram monofilament is specified as the primary instrument for LOPS assessment in every edition of the Standards of Care from 2018 through 2026.
View guideline →Prevention Guidelines, 2023 Update
"Loss of protective sensation can be assessed with a 10-gram Semmes-Weinstein monofilament, with consistent results found using this assessment to predict risk of foot ulcer."
The IWGDF 2023 guidelines establish a risk-stratified screening schedule: annually for IWGDF Risk 0, every 6-12 months for Risk 1, every 3-6 months for Risk 2, and every 1-3 months for Risk 3. The monofilament is the specified tool for LOPS assessment at every tier.
View guideline →Peer-Reviewed Research
Key studies on monofilament screening.
The following studies represent the core of the clinical evidence base for the 10-gram monofilament test. Each is indexed in PubMed and available for review.
Prediction of Incident Diabetic Neuropathy Using the Monofilament Examination: A 4-year Prospective Study
Diabetes Care, Vol. 33, No. 7, pp. 1549–1554. Published by the American Diabetes Association.
This four-year prospective study established that a threshold of five or fewer sensate stimuli out of eight during monofilament testing accurately discriminated patients who would develop diabetic neuropathy, with clinically meaningful sensitivity and specificity. The monofilament examination was found to be a practical, predictive tool for prospective neuropathy risk stratification, not merely a cross-sectional screening instrument.
View on Diabetes Care →Screening Techniques to Identify People at High Risk for Diabetic Foot Ulceration: A Prospective Multicenter Trial
Diabetes Care, Vol. 23, No. 5. PMID: 10834417.
This 248-patient multicenter prospective trial evaluated a battery of screening instruments, including neuropathy symptom score, neuropathy disability score, vibration perception threshold, Semmes-Weinstein monofilaments, joint mobility, plantar pressure, and vascular status, for their association with foot ulceration. Monofilament testing was identified as one of the most practical and predictive instruments, supporting its use as a first-line screening tool in clinical settings.
View on PubMed →Diagnostic Accuracy of Monofilament Tests for Detecting Diabetic Peripheral Neuropathy: A Systematic Review and Meta-Analysis
Journal of Diabetes Research, 2017. PMID: 29119118. PMC: PMC5651135.
This systematic review and meta-analysis pooled data across multiple studies assessing the diagnostic accuracy of monofilament testing for diabetic peripheral neuropathy. The analysis confirmed that the 10-gram monofilament is the most widely validated first-line screening instrument for loss of protective sensation, and highlighted that diagnostic performance is sensitive to testing protocol, specifically the number of sites tested and the consistency of filament calibration.
View on PubMed →Semmes-Weinstein Monofilaments: A Simple, Effective and Inexpensive Screening Device for Identifying Diabetic Patients at Risk of Foot Ulceration
Diabetic Medicine, Vol. 8, No. 5. PMID: 1773715.
One of the foundational papers establishing the clinical utility of the Semmes-Weinstein monofilament for diabetic foot screening. This study demonstrated that the monofilament test is a simple, practical, and cost-effective method for identifying patients at elevated risk of foot ulceration, conclusions that have been replicated and expanded upon across 30+ years of subsequent research and are reflected in current international guidelines.
View on PubMed →The Calibration Problem
Why device quality determines test validity.
The diagnostic value of the monofilament test depends on the instrument delivering a consistent 10 gram force range, ±1.5 g. Research has documented that monofilament stiffness degrades with repeated use, a filament used on multiple patients, or in varying temperature and humidity conditions, may no longer deliver the force it was manufactured to produce.
A 2024 calibration study published in PMC (PMC11429209) examined the mechanical properties of Semmes-Weinstein monofilaments and confirmed that force output is sensitive to environmental conditions and filament age. This supports the FDA's designation of monofilaments as single-use devices and underscores why manufacturing precision is a clinical variable, not just a product specification.
When the instrument is unreliable, the test is unreliable, regardless of how carefully the protocol is followed. A patient who fails to detect a degraded filament may be classified as normal when they are not. That error has consequences.
2024, PMC11429209
Calibration and Modeling of the Semmes-Weinstein Monofilament for Diabetic Foot Management
Confirmed that monofilament force output is affected by environmental variables including relative humidity and temperature, and that consistent force delivery requires both proper manufacturing tolerances and single-use protocols.
View on PMC →FDA Classification
Monofilaments are FDA Class I, single-use medical devices. Single use also prevents cross-contamination between patients, in line with universal precautions. Each filament is designed to deliver the 10 gram force range, ±1.5 g, for a single test. Reuse introduces force variability that degrades the clinical reliability of the result.
Medical Monofilament
The only FDA-cleared monofilament manufacturer in the U.S.
510(k) clearance means our device has been reviewed by the FDA for safety and effectiveness, the same standard applied to other regulated medical devices. No other monofilament manufacturer in the United States holds this designation.
Our patented automated manufacturing process uses precision inline sensors and daily gram-scale calibration to verify every unit before it ships. The clinical evidence for monofilament testing is only as strong as the device being used. We build ours to hold up to that standard.